Ed F. Haislmaier, the Preston A. Wells Jr senior research fellow at the Institute for Family, Community, and Opportunity at The Heritage Foundation, discusses the policies under the Trump administration and how they will affect financial burdens.
Ed F. Haislmaier, the Preston A. Wells Jr senior research fellow at the Institute for Family, Community, and Opportunity at The Heritage Foundation, discusses the policies under the Trump administration and how they will affect financial burdens.
Transcript
Do you think the Trump administration’s decision to extend the life short-term health plans will have an impact on the financial hardships many patients face?
The Trump administration’s move to restore the previous definition of short term plans would provide an out in the near term for people who are self-employed, for example, and get no subsidies for coverage because they would be able to have less expensive coverage. Over the longer run, I think those people will probably move towards association plans which is something else that the Trump administration put forward.
What policy change might help alleviate financial burdens facing patients as new, potentially curative but expensive, treatments come to market to ensure patients have access to these innovative medications?
The treatments are primarily pharmaceutical therapies, biologics in particular. I think we’re seeing already in the private sector integrating those benefits with hospital and physicians. Otherwise, not treating them as separate. We have situations where yes, the pharmaceutical therapy is expensive but it’s not different than a surgery, it’s just were more used to paying large dollars for a surgery opposed to paying large dollars for pharmacy. The use of separate deductibles and things like that is sort of going away in the private market. The government programs, particularly Medicare, haven’t kept up with that and that’s where it needs to be integrated.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
February 16th 2025Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.
Read More